Status:
COMPLETED
Efficacy and Tolerability of Xalatan in Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18-65 years
Brief Summary
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.
Detailed Description
* Efficacy data not collected or analyzed * Safety and tolerability of Xalatan assessed NA
Eligibility Criteria
Inclusion
- Patient with ocular hypertension at least 22mg Hg
- Patient must be over 18 years old
Exclusion
- None listed in the protocol
Key Trial Info
Start Date :
July 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
1289 Patients enrolled
Trial Details
Trial ID
NCT00950690
Start Date
July 1 2005
End Date
December 1 2007
Last Update
February 25 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alexandria, Egypt
2
Pfizer Investigational Site
Jeddah, Saudi Arabia
3
Pfizer Investigational Site
Umm Al Quwain City, United Arab Emirates